Prot #WO40242: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of Atezolizumab (Anti-PD-L1 Antibody) As Adjuvant Therapy After Definitive Local Therapy In Patients With High-Risk Locally Advanced Squamous Cell Carcinoma Of Th